title: [Multifocal cutaneous leishmaniasis due to Leishmania infantum under adalimumab therapy].
authors.forename: P
authors.initials: P
authors.lastname: Schneider
authors.forename: J D
authors.initials: JD
authors.lastname: Bouaziz
authors.forename: F
authors.initials: F
authors.lastname: Foulet
authors.forename: T A
authors.initials: TA
authors.lastname: Duong
authors.forename: L Valeyrie
authors.initials: LV
authors.lastname: Allanore
authors.forename: M
authors.initials: M
authors.lastname: Bagot
mesh_terms: D000068879:Adalimumab; D000666:Amphotericin B / Q000627:therapeutic use*; D000818:Animals; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D000981:Antiprotozoal Agents / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000009:adverse effects*; D005260:Female; D006801:Humans; D018314:Leishmania infantum; D016773:Leishmaniasis, Cutaneous / Q000139:chemically induced* / Q000188:drug therapy*; D008875:Middle Aged; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000981:Antiprotozoal Agents; D018501:Antirheumatic Agents; D014409:Tumor Necrosis Factor-alpha; D000666:Amphotericin B; D000068879:Adalimumab